Ratings GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E. Other stock markets 11:35:27 2024-04-25 am EDT			5-day change	1st Jan Change
1,640 ^GBX	+0.28%		+3.60%	+13.12%

07:58pm	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
07:00pm	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company appears highly valued given the size of its balance sheet.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GSK PLC	+13.12%	83.1B	B
NOVO NORDISK A/S	+24.17%	562B	B
JOHNSON & JOHNSON	-6.28%	358B	C+
MERCK & CO., INC.	+19.20%	322B	B-
ABBVIE INC.	+7.48%	297B	C+
ASTRAZENECA PLC	+13.45%	219B	B+
NOVARTIS AG	+6.04%	199B	B-
ROCHE HOLDING AG	-10.51%	196B	A+
PFIZER, INC.	-11.88%	149B	C+
AMGEN INC.	-6.48%	146B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes